Compare ABT & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABT | NVO |
|---|---|---|
| Founded | 1888 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | 69500 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.3B | 166.1B |
| IPO Year | 2006 | N/A |
| Metric | ABT | NVO |
|---|---|---|
| Price | $95.58 | $40.42 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 20 | 11 |
| Target Price | ★ $130.95 | $51.00 |
| AVG Volume (30 Days) | 8.4M | ★ 13.1M |
| Earning Date | 04-16-2026 | 05-06-2026 |
| Dividend Yield | 2.60% | ★ 3.17% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.72 | N/A |
| Revenue | ★ $44,328,000,000.00 | N/A |
| Revenue This Year | $10.75 | N/A |
| Revenue Next Year | $8.10 | $3.88 |
| P/E Ratio | $26.01 | ★ $13.60 |
| Revenue Growth | ★ 5.67 | N/A |
| 52 Week Low | $93.92 | $35.12 |
| 52 Week High | $137.49 | $81.44 |
| Indicator | ABT | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 28.54 | 59.23 |
| Support Level | N/A | $35.49 |
| Resistance Level | $103.84 | $50.30 |
| Average True Range (ATR) | 2.21 | 1.02 |
| MACD | -0.40 | 0.74 |
| Stochastic Oscillator | 16.15 | 84.15 |
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.